Merck (MRK) Non-Current Deferred Tax Liability (2009 - 2026)

Merck has disclosed Non-Current Deferred Tax Liability across 18 years of filings, most recently posting $1.5 billion for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 6.03% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 6.03% YoY), while the FY2025 annual figure was $1.4 billion, down 52.91% from the prior year.
• Non-Current Deferred Tax Liability grew to $1.5 billion in Q1 2026, from $1.4 billion in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for MRK reached as high as $3.1 billion in Q1 2022 and fell as low as $864.0 million in Q3 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $1.4 billion (2025), against an average of $1.7 billion.
• Annual changes were most pronounced in 2022 — Non-Current Deferred Tax Liability soared 155.07% — and 2023, when it plunged 66.51%.
• A 5-year view of Non-Current Deferred Tax Liability shows it stood at $1.8 billion in 2022, then jumped by 64.79% to $3.0 billion in 2023, then increased by 3.31% to $3.1 billion in 2024, then slumped by 52.91% to $1.4 billion in 2025, then rose by 3.82% to $1.5 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.5 billion, $1.4 billion, and $1.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.